How I treat heterozygous hereditary antithrombin deficiency in pregnancy

summary

Untreated hereditary antithrombin deficiency in pregnancy is associated with maternal venous thromboembolism (VTE) and possibly with fetal loss. Thromboprophylaxis during pregnancy is recommended, but dosages remain controversial. Our objective was to perform a retrospective assessment of thrombotic events and pregnancy outcomes in women with hereditary antithrombin deficiency managed according to a standard protocol. Pregnancies in individuals with hereditary antithrombin deficiency were identified from a hospital database. Women with no prior VTE received enoxaparin 40 mg daily until 16 weeks gestation and thereafter 40 mg twice daily. Women with prior VTE received intermediate dose enoxaparin (1 mg/kg) once daily, increased to twice daily at 16 weeks and anti-Xa monitored dosing. Thromboprophylaxis was stopped at initiation of labour or 12 hours prior to caesarean and 50 IU/kg antithrombin concentrate given. Thromboprophylaxis was restarted after delivery. Eighteen pregnancies in 11 women with antithrombin deficiency were identified. Seventeen pregnancies (94%) were successful. Median gestation was 39 weeks (range 30–41) and median birth-weight was 2,995 g (910–4,120 g),but 6/17 infants (35%) were small for gestational age (p=0.01). Estimated blood loss at delivery was median 375 ml (200–600 ml). Four pregnancies were complicated by VTE; one newly presented with a thrombotic event, two patients were not taking thromboprophylaxis and one occurred despite thromboprophylaxis. Two novel mutations(p.Leu317Ser and p.His33GInfsX32) are described. In conclusion, in antithrombin deficiency the use of low-molecular-weight heparin in pregnancy and puerperium with antithrombin concentrate predelivery was associated with successful pregnancy outcome; rates of VTE appear to be lower than previously reported, but remain elevated

Keywords

Hereditary antithrombin deficiency - pregnancy

• References

• 1 Lane DA, Bayston T, Olds RJ. et al. Antithrombin mutation database: 2nd (1997) update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1997; 77: 197-211.
• 2 Roemisch J, Gray E, Hoffmann JN. et al. Antithrombin: a new look at the actions of a serine protease inhibitor. Blood Coagul Fibrinolysis 2002; 13: 657-670.
• 3 Haemostasis and Thrombosis Task Force. Investigation and management of heritable thrombophilia. Br J Haematol 2001; 114: 512-528.
• 4 Wells PS, Blajchman MA, Henderson P. et al. Prevalence of antithrombin deficiency in healthy blood donors: a cross-sectional study. Am J Hematol 1994; 45: 321-324.
• 5 Tait RC, Walker ID, Perry DJ. et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 1994; 87: 106-112.
• 6 Hirsh J, Piovella F, Pini M. Congenital antithrombin III deficiency. Incidence and clinical features. Am J Med 1989; 87: 34S-38S.
• 7 Lockwood CJ. Inherited thrombophilias in pregnant patients: detection and treatment paradigm. Obstet Gynecol 2002; 99: 333-341.
• 8 Mitic G, Povazan L, Lazic R. et al. Deficiency of the natural anticoagulant proteins in women with pregnancy related venous thromboembolism. Med Pregl 2009; 62: 53-62.
• 9 McColl MD, Ramsay JE, Tait RC. et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997; 78: 1183-1188.
• 10 Conard J, Horellou MH, Van Dreden P. et al. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women. Thromb Haemos 1990; 63: 319-320.
• 11 Hellgren M, Tengborn L, Abildgaard U. Pregnancy in women with congenital antithrombin III deficiency: experience of treatment with heparin and antithrombin. Gynecol Obstet Invest 1982; 14: 127-141.
• 12 Preston FE, Rosendaal FR, Walker ID. et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996; 348: 913-916.
• 13 Vicente V, Rodriguez C, Soto I. et al. Risk of thrombosis during pregnancy and post-partum in hereditary thrombophilia. Am J Hematol 1994; 46: 151-152.
• 14 Sharpe CJ, Crowther MA, Webert KE. et al. Cerebral venous thrombosis during pregnancy in the setting of type I antithrombin deficiency: case report and literature review. Transfus Med Rev 2011; 25: 61-65.
• 15 Szilagyi A, Nagy A, Tamas P. et al. Two successful pregnancies following eight miscarriages in a patient with antithrombin deficiency. Gynecol Obstet Invest 2006; 61: 111-114.
• 16 Sabadell J, Casellas M, Alijotas-Reig J. et al. Inherited antithrombin deficiency and pregnancy: maternal and fetal outcomes. Eur J Obstet Gynecol Reprod Biol 2010; 149: 47-51.
• 17 Yamada T, Yamada H, Morikawa M. et al. Management of pregnancy with congenital antithrombin III deficiency: two case reports and a review of the literature. J Obstet Gynaecol Res 2001; 27: 189-197.
• 18 De Stefano V, Leone G, De Carolis S. et al. Management of pregnancy in women with antithrombin III congenital defect: report of four cases. Thromb Haemost 1988; 59: 193-196.
• 19 Nelson DM, Stempel LE, Brandt JT. Hereditary antithrombin III deficiency and pregnancy: report of two cases and review of the literature. Obstet Gynecol 1985; 65: 848-853.
• 20 Hunt BJ, Gattens M, Khamashta M. et al. Thromboprophylaxis with unmonitored intermediate-dose low molecular weight heparin in pregnancies with a previous arterial or venous thrombotic event. Blood Coagul Fibrinolysis 2003; 14: 735-739.
• 21 McAuley WJ, Hunt BJ, Ahmad HN. et al. First trimester superior sagittal sinus venous thrombosis and antithrombin deficiency. J Obstet Gynaecol 2005; 25: 808-810.
• 22 Folkeringa N, Brouwer JL, Korteweg FJ. et al. Reduction of high fetal loss rate by anticoagulant treatment during pregnancy in antithrombin, protein C or protein S deficient women. Br J Haematol 2007; 136: 656-661.
• 23 Arias F, Romero R, Joist H. et al. Thrombophilia: a mechanism of disease in women with adverse pregnancy outcome and thrombotic lesions in the placenta. J Matern Fetal Med 1998; 07: 277-286.
• 24 Perry SL, Ortel TL. Clinical and laboratory evaluation of thrombophilia. Clin Chest Med 2003; 24: 153-170.
• 25 Thaler E, Lechner K. Antithrombin III deficiency and thromboembolism. Clin Haematol 1981; 10: 369-390.
• 26 Friederich PW, Sanson BJ, Simioni P. et al. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med 1996; 125: 955-960.
• 27 Bates SM, Greer IA, Middeldorp S. et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e691S-e736S.
• 28 Maclean PS, Tait RC. Hereditary and acquired antithrombin deficiency: epidemiology, pathogenesis and treatment options. Drugs 2007; 67: 1429-1440.
• 29 Schulman S, Tengborn L. Treatment of venous thromboembolism in patients with congenital deficiency of antithrombin III. Thromb Haemost 1992; 68: 634-636.
• 30 Thomas J, Callwood A, Brocklehurst P. et al. The National Sentinel Caesarean Section Audit. Br J Obstet Gynecol 2000; 107: 579-580.
• 31 Paternoster DM, Fantinato S, Manganelli F. et al. Efficacy of AT in pre-eclampsia: a case-control prospective trial. Thromb Haemost 2004; 91: 283-289.
• 32 Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001; 344: 1222-1231.
• 33 Martinelli I, Mannucci PM, De Stefano V. et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998; 92: 2353-2358.
• 34 Finazzi G, Caccia R, Barbui T. Different prevalence of thromboembolism in the subtypes of congenital antithrombin III deficiency: review of 404 cases. Thromb Haemost 1987; 58: 1094